Table 1: Baseline characteristics of the patients (demographic data, biochemistry analysis, Pulmonary function tests and echocardiographic parameters).
| Parameters | Atorvastatin group (n = 31) | Placebo group (n = 24) | p |
| Age | 65.35 ± 10.07 | 62.21 ± 11.11 | 0.28 |
| Male/female† | 21/10 | 17/7 | 0.81 |
| Heart Rate | 75.47 ± 10.57 | 75.67 ± 7.88 | 0.94 |
| Biochemistry Analysis | |||
| FBS (mg/dl) | 111.12 ± 36.84 | 104.79 ± 15.35 | 0.43 |
| Cholesterol (mg/dl) | 200.47 ± 39.42 | 187.00 ± 48.10 | 0.26 |
| Triglyceride (mg/dl)‡ | 136.00 (84.00) | 108.00 (77.50) | 0.33 |
| LDL (mg/dl) | 126.42 ± 30.49 | 121.67 ± 27.45 | 0.55 |
| HDL (mg/dl) | 43.56 ± 10.06 | 46.87 ± 9.66 | 0.22 |
| SGPT (mg/dl)‡ | 21.00 (16.00) | 18.90 ± 7.01 | 0.07 |
| CPK (mg/dl) | 111.23 ± 80.47 | 91.53 ± 42.18 | 0.28 |
| Spirometry findings | |||
| FVC mean | 2.27 ± 0.77 | 2.88 ± 1.55 | 0.08 |
| FVC predicted% | 74.60 ± 20.82 | 80.47 ± 29.36 | 0.39 |
| FEV1 mean | 1.39 ± 0.59 | 1.67 ± 1.06 | 0.25 |
| FEV1 predicted% | 57.61 ± 21.38 | 64.30 ± 32.55 | 0.36 |
| FEV1/FVC | 61.02 ± 13.57 | 61.27 ± 12.44 | 0.94 |
| MMEF‡ | 0.68 (0.74) | 0.77 (0.89) | 0.75 |
| MMEF predicted%‡ | 32.90 (29.90) | 27.25 (38.80) | 0.86 |
| Echocardiographic Parameters | |||
| Mid RV diameter (cm)‡ | 3.6 (1.13) | 3.61 ± 0.69 | 0.86 |
| RA area (cm2) | 14.88 ± 2.04 | 14.77 ± 1.92 | 0.85 |
| LVEF (%) | 56.93 ± 3.70 | 57.53 ± 2.46 | 0.50 |
| Sm (cm/sec) | 10.72 ± 1.61 | 10.68 ± 1.21 | 0.92 |
| TA Em (cm/sec) | 8.64 ± 1.97 | 8.70 ± 1.99 | 0.91 |
| TA Am (cm/sec) | 16.29 ± 2.92 | 14.89 ± 2.53 | 0.07 |
| TV E (m/sec) | 38.16 ± 7.01 | 41.20 ± 7.20 | 0.91 |
| TV E/TA Em | 4.90 ± 1.19 | 5.27 ± 1.52 | 0.61 |
| RV SRB | - 24.19 ± 2.66 | - 23.65 ± 2.59 | 0.45 |
| RV SRM | - 29.96 ± 2.88 | - 30.49 ± 3.92 | 0.57 |
| PAP | 38.49 ± 7.15 | 34.74 ± 8.33 | 0.08 |
| GLS | - 15.11 ± 6.77 | - 16.40 ± 1.22 | 0.36 |
Abbreviations: CPK: Creatine Phosphokinase; FBS: Fasting Blood Glucose; FEV1: Forced Expiratory Volume in the First Minute; FVC: Forced Vital Capacity; GLS: Global Longitudinal Strain; LDL: Low Density Lipoprotein; LVEF: Left Ventricle Ejection Fraction; HDL: High Density Lipoprotein; MMEF: Maximum Mid Expiratory Flow; PAP: Pulmonary Artery Pressure; RA: Right Atrium; RV: Right Ventricle; SGPT: Serum Glutamate-Pyruvic Transaminase; SRB: Longitudinal Strain in Basal Segment of RV Free Wall; SRM: Longitudinal Strain in Mid Segment of RV Free Wall; TA: Tricuspid Annulus; TV: Tricuspid Valve.
Mean and SD were shown for all variables and the independent t-test was used for the comparison except for triglyceride, SGPT, MMEF, MMEF predicted%, mid RV diameter and gender.
†The Chi-square test was performed for the comparison of gender distribution pattern in atorvastatin and placebo groups; ‡Median and interquartile range (IQR) were shown. The Mann-Whitney test was performed for the comparison.